Science at the Edge Seminar Series

Quantitative Biology Graduate Program/ Gene Expression in Development and Disease

Dr. Shirley Liu

School of Public Health Harvard University

"Using Epigenetic Profiling and CRISPR Screens to Understand Cancer Progression and Drug Response"

With the recent exciting development of high throughput sequencing applications, epigenetic profiling and CRISPR screens have become important tool boxes for cancer research. I will introduce the following two projects in the lab.

First, I will discuss how to utilize H3K27ac ChIP-seq data to better model gene regulation. By distant-weighting the H3K27ac ChIP-seq reads and integrating publicly available H3K27ac ChIP-seq data, we found an effective method to better identify genes activated or repressed by the BET inhibitor JQ1. We discovered that when given a list of differential genes between cell conditions, we could use a regression method to extract relevant public H3K27ac ChIP-seq and identify relevant enhancers that might regulate the differential expression of the genes of interests.

In the second part, I will discuss our computational work on facilitating genome-wide CRISPR/Cas9 knockout screens. We developed a sequence model to identify efficient sgRNAs for for CRISPR screens and built MAGeCK / VISPR to analyze and visualize CRISPR screen results. We also designed a network analysis method to predict essential genes in a cell and prioritize CRISPR screen results. Finally I will demonstrate how we use CRISPR screens to study breast and prostate cancer progression into hormone independence.

Friday, October 23, 2015 at 11:30a.m. Room 1400 BPS

Refreshments at 11:15